AS01 treatment reduced tumor growth in preclinical melanoma and bladder cancer mouse models. (IMAGE)
Caption
C57BL/6 mice were injected with B16-F10 or MB49 cells and then treated with intramuscular PBS or AS01 at the specified days relative to tumor injection. (a) Experimental design for the B16-F10 melanoma model; (b) Mice received either two doses of PBS or one or two doses of 10 or 20 μg AS01 at days 0 and 4 after B16-F10 injection. Tumor volumes were monitored for 16 days after tumor inoculation (n = 7 mice for the PBS group, n = 9 for 10 μg AS01 single dose, n = 9 for 10 μg AS01 double dose, n = 10 for 20 μg AS01 single dose, n = 10 for 20 μg AS01 double dose); (c) Experimental design for the MB49 bladder cancer model. Only the double injection (day 0 + day 4) of the higher AS01 concentration was employed in the bladder cancer model; (d) Mice received either two doses of PBS or 20 μg AS01 at days 0 and 4 after MB49 injection; Tumor volumes were monitored for 13 days after tumor inoculation (n = 10 mice for the PBS group, n = 9 for the AS01 group) (e) Excised MB49 tumor weights at day 13 after tumor inoculation. Data are shown as mean ± SD, p values obtained by one-way ANOVA on day 16 tumor volumes (b) and two-way ANOVA (d) with Tukey’s multiple comparisons and unpaired t test (E), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001. PBS: phosphate buffered saline.
Credit
© Mihai G. Netea, et al. 2026. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Usage Restrictions
Credit must be given to the creator.
License
CC BY